Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 386

1.

Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification.

Chen CC, Chu CB, Liu KJ, Huang CY, Chang JY, Pan WY, Chen HH, Cheng YH, Lee KD, Chen MF, Kuo CC, Chen LT.

Biochem Pharmacol. 2013 Oct 1;86(7):872-87. doi: 10.1016/j.bcp.2013.07.025. Epub 2013 Aug 8.

PMID:
23933386
2.

Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil.

Chen CC, Chen LT, Tsou TC, Pan WY, Kuo CC, Liu JF, Yeh SC, Tsai FY, Hsieh HP, Chang JY.

Br J Cancer. 2007 Aug 6;97(3):334-44. Epub 2007 Jul 3.

3.

Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.

Yanagie H, Hisa T, Ogata A, Miyazaki A, Nonaka Y, Nishihira T, Osada I, Sairennji T, Sugiyama H, Furuya Y, Kidani Y, Takamoto S, Takahashi H, Eriguchi M.

Biomed Pharmacother. 2009 Sep;63(8):553-60. doi: 10.1016/j.biopha.2008.04.006. Epub 2008 May 27.

PMID:
18571892
4.

Bilirubin mediated oxidative stress involves antioxidant response activation via Nrf2 pathway.

Qaisiya M, Coda Zabetta CD, Bellarosa C, Tiribelli C.

Cell Signal. 2014 Mar;26(3):512-20. doi: 10.1016/j.cellsig.2013.11.029. Epub 2013 Dec 2.

PMID:
24308969
5.
6.
7.

Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway.

Gao AM, Ke ZP, Shi F, Sun GC, Chen H.

Chem Biol Interact. 2013 Oct 25;206(1):100-8. doi: 10.1016/j.cbi.2013.08.008. Epub 2013 Aug 27.

PMID:
23994249
8.

Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway.

Shim GS, Manandhar S, Shin DH, Kim TH, Kwak MK.

Free Radic Biol Med. 2009 Dec 1;47(11):1619-31. doi: 10.1016/j.freeradbiomed.2009.09.006. Epub 2009 Sep 12.

PMID:
19751820
9.

Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.

Tozawa K, Oshima T, Kobayashi T, Yamamoto N, Hayashi C, Matsumoto T, Miwa H.

Anticancer Res. 2008 Jul-Aug;28(4B):2087-92.

10.

[Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].

Wang Y, Li LZ, Ye L, Niu XL, Liu X, Zhu YQ, Sun WJ, Liang YJ.

Zhonghua Fu Chan Ke Za Zhi. 2010 Sep;45(9):691-8. Chinese.

PMID:
21092551
11.

Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity.

Shiiba M, Yamagami H, Yamamoto A, Minakawa Y, Okamoto A, Kasamatsu A, Sakamoto Y, Uzawa K, Takiguchi Y, Tanzawa H.

Oncol Rep. 2017 Apr;37(4):2025-2032. doi: 10.3892/or.2017.5480. Epub 2017 Mar 1.

PMID:
28259989
13.

Up-down regulation of HO-1 and iNOS gene expressions by ethyl pyruvate via recruiting p300 to Nrf2 and depriving It from p65.

Kim SW, Lee HK, Shin JH, Lee JK.

Free Radic Biol Med. 2013 Dec;65:468-76. doi: 10.1016/j.freeradbiomed.2013.07.028. Epub 2013 Jul 24.

PMID:
23891677
14.

Oxaliplatin activates the Keap1/Nrf2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs.

Wang XJ, Li Y, Luo L, Wang H, Chi Z, Xin A, Li X, Wu J, Tang X.

Free Radic Biol Med. 2014 May;70:68-77. doi: 10.1016/j.freeradbiomed.2014.02.010. Epub 2014 Feb 18.

PMID:
24556415
15.

Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs.

Tang X, Wang H, Fan L, Wu X, Xin A, Ren H, Wang XJ.

Free Radic Biol Med. 2011 Jun 1;50(11):1599-609. doi: 10.1016/j.freeradbiomed.2011.03.008. Epub 2011 Mar 12.

PMID:
21402146
16.

Aldo-keto reductase 1C subfamily genes in skin are UV-inducible: possible role in keratinocytes survival.

MarĂ­n YE, Seiberg M, Lin CB.

Exp Dermatol. 2009 Jul;18(7):611-8. doi: 10.1111/j.1600-0625.2008.00839.x. Epub 2009 Mar 6.

PMID:
19320734
18.
19.

3',4',5',5,7-pentamethoxyflavone sensitizes Cisplatin-resistant A549 cells to Cisplatin by inhibition of Nrf2 pathway.

Hou X, Bai X, Gou X, Zeng H, Xia C, Zhuang W, Chen X, Zhao Z, Huang M, Jin J.

Mol Cells. 2015 May;38(5):396-401. doi: 10.14348/molcells.2015.2183. Epub 2015 Mar 31.

20.

Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells.

Kim SK, Yang JW, Kim MR, Roh SH, Kim HG, Lee KY, Jeong HG, Kang KW.

Free Radic Biol Med. 2008 Aug 15;45(4):537-46. doi: 10.1016/j.freeradbiomed.2008.05.011. Epub 2008 May 24.

PMID:
18539158

Supplemental Content

Support Center